Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-21 07:30 |
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
|
English | 231.4 KB | ||
| 2024-12-04 07:30 |
Nicox annonce la première vente commerciale de ZERVIATE en Chine par son parten…
|
French | 244.9 KB | ||
| 2024-12-04 07:30 |
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumensio…
|
English | 225.6 KB | ||
| 2024-12-02 07:30 |
Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude…
|
French | 258.9 KB | ||
| 2024-12-02 07:30 |
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Ex…
|
English | 249.6 KB | ||
| 2024-11-21 10:24 |
Franchissement de seuils
|
French | 272.1 KB | ||
| 2024-11-19 07:30 |
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont B…
|
English | 219.6 KB | ||
| 2024-11-19 07:30 |
Nicox annonce la publication de la partie adaptive de l’étude clinique de phase…
|
French | 233.2 KB | ||
| 2024-10-17 07:30 |
Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers…
|
French | 431.8 KB | ||
| 2024-10-17 07:30 |
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
|
English | 391.1 KB | ||
| 2024-10-14 07:30 |
Nicox et Soleus signent un accord de financement de 16,5 millions de dollars co…
|
French | 439.5 KB | ||
| 2024-10-14 07:30 |
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
|
English | 330.5 KB | ||
| 2024-09-18 07:30 |
Nicox annonce l’approbation de ZERVIATE en Chine
|
French | 236.6 KB | ||
| 2024-09-18 07:30 |
Nicox Announces Approval of ZERVIATE in China
|
English | 227.6 KB | ||
| 2024-09-04 07:30 |
Nicox nomme Christine Placet administrateur ; Michele Garufi se retire du Conse…
|
French | 175.0 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
